ALK and non-small cell lung carcinoma: We aimed to evaluate the incidence of this adverse effect.<h4>Methods</h4>We retrospectively evaluated imaging studies of all patients in our institution receiving TKI for ALK-rearranged or ROS1-positive NSCLC (crizotinib, alectinib, lorlatinib, brigatinib).<h4>Results</h4>Between February 2012 and August 2023, out of a total number of 71 subjects (51% male, 36-88 years old) who received TKI's for ALK-rearranged/ ROS1 positive NSCLC, 34/71 (47%) were exposed at least once to crizotinib treatment, while the other 37/71 (53%) patients received other TKI's.